Relationship between matrix metalloproteinase-3 levels and articular destructive changes in early and extended rheumatoid arthritis
- 作者: Avdeeva A1, Aleksandrova E1, Karateev D1, Panasyuk E1, Smirnov A1, Cherkasova M1, Nasonov E1
-
隶属关系:
- Научно-исследовательский институт ревматологии им. В.А. Насоновой
- 期: 卷 88, 编号 5 (2016)
- 页面: 13-18
- 栏目: Editorial
- URL: https://journals.rcsi.science/0040-3660/article/view/31961
- ID: 31961
如何引用文章
全文:
详细
作者简介
A Avdeeva
Научно-исследовательский институт ревматологии им. В.А. НасоновойМосква, Россия
E Aleksandrova
Научно-исследовательский институт ревматологии им. В.А. НасоновойМосква, Россия
D Karateev
Научно-исследовательский институт ревматологии им. В.А. НасоновойМосква, Россия
E Panasyuk
Научно-исследовательский институт ревматологии им. В.А. НасоновойМосква, Россия
A Smirnov
Научно-исследовательский институт ревматологии им. В.А. НасоновойМосква, Россия
M Cherkasova
Научно-исследовательский институт ревматологии им. В.А. НасоновойМосква, Россия
E Nasonov
Научно-исследовательский институт ревматологии им. В.А. НасоновойМосква, Россия
参考
- Насонов Е.Л., Каратеев Д.Е., Балабанова Р.М. Ревматоидный артрит. В кн.: Ревматология. Национальное руководство. Под ред. Насонова Е.Л., Насоновой В.А. М.: ГЭОТАР-Медиа; 2008:290-331.
- Shovman O, Gilburd B, Zandman-Goddard G et al. The diagnostic utility of anti-cyclic citrullinated peptide antibodies, matrix metalloproteinase-3, rheumatoid factor, erythrocyte sedimentation rate, and C-reactive protein in patients with erosive and non-erosive rheumatoid arthritis. Clin Dev Immunol. 2005:12(3):197-202. doi: 10.1080/17402520500233510.
- Schett G. Cells of the synovium in rheumatoid arthritis. Osteoclasts. Arthritis Res Ther. 2007;9:203. doi: 10.1186/ar2110.
- Burrage P, Mix K, Brinckerhoff C. Matrix metalloproteinases: role in arthritis. Front Biosci. 2006;11:529-543. doi: 10.2741/1817.
- Murphy G, Knauper V, Atkinson S et al. Matrix metalloproteinases in arthritic disease. Arthritis Res. 2002;4(Suppl 3):39-49. doi: 10.1186/ar572.
- Flannery C. MMPs and ADAMTSs: functional studies. Front Biosci. 2006;11:544-569. doi: 10.2741/1818.
- Ribbens C, Andre B, Kaye O et al. Synovial fluid matrix metalloproteinase 3 levels are increased in inflammatory arthritis whether erosive or not. Rheumatology. 2000;39:1357-1365. doi: 10.1093/rheumatology/39.12.1357.
- Ronday HK, Smits HH, Van Muijen GN et al. Difference in expression of the plasminogen activation system in synovial tissue of patients with rheumatoid arthritis and osteoarthritis. Br J Rheumatol. 1996;35(5):416-423. doi: 10.1093/rheumatology/35.5.416.
- Bonassar L, Frank E, Murray J et al. Grodzinsky: Changes in cartilage composition and physical properties due to stromelysin degradation. Arthritis Rheum. 1995;38(2):173-183. doi: 10.1002/art.1780380205.
- Unemori E, Bair M, Bauer E et al. Amento: Stromelysin expression regulates collagenase activation in human fibroblasts. Dissociable control of two metalloproteinases by interferon-gamma. J Biol Chem. 1991;266(34):23477-23482. doi: 10.1002/(sici)1097-4644(19990301)72:3<373::aid-jcb7>3.0.co;2-n.
- Kobayashi A, Naito S, Enomoto H et al. Serum levels of matrix metalloproteinase 3 (stromelysin 1) for monitoring synovitis in rheumatoid arthritis. Arch Pathol Lab Med. 2007;131:563-570. doi: 10.1002/1529-0131(200011)43:11<2614::aid-anr36>3.0.co;2-h.
- Syversen S, Haavardsholm E, Bøyesen P et al. Biomarkers in early rheumatoid arthritis: longitudinal associations with inflammation and joint destruction measured by magnetic resonance imaging and conventional radiographs. Ann Rheum Dis. 2010;69:845-850. doi: 10.1136/ard.2009.122325.
- Green M, Gough A, Devlin J et al. Serum MMP-3 and MMP-1 and progression of joint damage in early rheumatoid arthritis. Rheumatology. 2003;42:83-88. doi: 10.1093/rheumatology/keg037.
- Yamanaka H, Matsuda Y, Tanaka M et al. Serum matrix metalloproteinase 3 as a predictor of the degree of joint destruction during the six months after measurement, in patients with early rheumatoid arthritis. Arthritis Rheum. 2000;43:852-858. doi: 10.1002/1529-0131(200004)43:4<852::aid-anr16>3.0.co;2-7.
- Fujikawa K, Kawakami A, Tamai M et al. High serum cartilage oligomeric matrix protein determines the subset of patients with early-stage rheumatoid arthritis with high serum C-reactive protein, matrix metalloproteinase-3, and MRI-proven bone erosion. J Rheumatol. 2009;36:1126-1129. doi:org/10.3899/jrheum.080926.
- Fuchs HA, Kaye JJ, Callahan LF, Nance EP, Pincus T. Evidence of significant radiographic damage in rheumatoid arthritis within the first 2 years of disease. J Rheumatol. 1989;16:585-591.
- Aletaha D, Neogi T, Silman AJ et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2010;69:1580-1588. doi: 10.1136/ard.2010.138461.
- Каратеев Д.Е., Лучихина Е.Л., Муравьев Ю.В., Демидова Н.В., Гринева Г.И., Новикова Д.С., Александрова Е.Н., Новиков А.А., Смирнов А.В., Волков А.В., Авдеева А.С., Лопарева Е.В., Олюнин Ю.А., Лукина Г.В., Попкова Т.В., Насонов Е.Л. Первое российское стратегическое исследование фармакотерапии ревматоидного артрита (РЕМАРКА). Научно-практическая ревматология. 2013;2:117-126. doi: 10.14412/1995-4484-2013-637.
- Van der Heijde D, Boers M, Lassere M. Methodological issues in radiographic scoring methods in rheumatoid arthritis. J Rheumatol. 1999;26:726-730.
- Tchetverikov I, Lard LR, DeGroot J. et al. Matrix metalloproteinases- 3, -8, -9 as markers of disease activity and joint damage progression in early rheumatoid arthritis. Ann. Rheum Dis. 2003; 62(11):1094-1099. doi: 10.1136/ard.62.11.1094.
- Galil S, El-Shafey A, Hagrass H et al. Baseline serum level of matrix metalloproteinase-3 as a biomarker of progressive joint damage in rheumatoid arthritis patients. Int J Rheum Dis. 2014. doi: 10.1111/1756-185X.12434.
- Yamanaka H, Matsuda Y, Tanaka M et al. Serum matrix metalloproteinase 3 as a predictor of the degree of joint destruction during the six months after measurement, in patients with early rheumatoid arthritis. Arthritis Rheum. 2000;43:852-858. doi: 10.1002/1529-0131(200004)43:4<852::aid-anr16>3.0.co;2-7.
- Young-Min S, Cawston T, Marshall N et al. Biomarkers predict radiographic progression in early rheumatoid arthritis and perform well compared with traditional markers. Arthritis Rheum. 2007;56:3236-3247. doi: 10.1002/art.22923.
- Houseman M, Potter C, Marshall N et al. Baseline serum MMP-3 levels in patients with Rheumatoid Arthritis are still independently predictive of radiographic progression in a longitudinal observational cohort at 8 years follow up. Arthritis Res Ther. 2012; 14:R30. doi: 10.1186/ar3734.
- Mamehara A, Sugimoto T, Sudiyama D et al. Serum matrix Metalloproteinase-3 as predictor of joint destruction in rheumatoid arthritis, treated with non-biological disease modifying antirheumatiс drugs. Kobe J Med Sci. 2010;56:98-107.
- Shiozawa K, Yamane T, Murata M et al. Serum MMP-3 predicts a subgroup with no radiographic progression in rheumatoid arthritis patients with low-dose methotrexate (MTX) monotherapy. Arthritis Rheum. 2014;66:abs.2925. doi: 10.1136/annrheumdis-2013-eular.2499.